GnRH agonist/antagonist

Phase 3Biologic

NNorthwestern University

GnRH agonist/antagonist is one of 81 biologic programs targeting Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Prostate CancerNot yet recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 3

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 3

Rubraca

Bristol-Myers Squibb

Phase 3

9 4

Glucophage

EMD Serono

Phase 3

14 5

Lhrha

Johnson & Johnson

Phase 3

2 6

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 7

GnRH agonist/antagonist

NNorthwestern University

Phase 3

2 8

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 9

Trexall

Duragesic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Prostate Cancer

NCT07783282

Q3 2029

Post-ApprovalActive, not recruiting

Prostate Cancer

NCT03016741

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Active, not recruiting·NNorthwestern University·Phase 4·NCT03016741·100 enrolled

A Phase 1 Open-label Study to Evaluate the Effect of Enzalutamide, Apalutamide and Bicalutamide on the Pharmacokinetics of Fezolinetant in Male Participants With Prostate Cancer

Not yet recruiting· Astellas logo

Astellas·Phase 1·NCT07783282·56 enrolled

Adenocarcinoma1 trial

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03436654·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for GnRH agonist/antagonist. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GnRH agonist/antagonist compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GnRH agonist/antagonist. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: NNorthwestern University

GnRH agonist/antagonist

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2029

Trials by Indication[1]

Prostate Cancer2 trials

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News